GlassScriptPhysician profile
Sylvia Yoon
NPI 1568919744
$1,211.78
in general payments reported to CMS, 2019-2025
19 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.50 · 2022: $214 · 2023: $155 · 2024: $331 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $271.38 | 2023-2025 | Vanflyta |
| Allergan, INC. | $147.22 | 2022 | |
| Novartis Pharmaceuticals Corporation | $110.62 | 2023-2024 | |
| Melinta Therapeutics, LLC | $80.20 | 2024-2025 | Rezzayo |
| Takeda Pharmaceuticals U.S.A., INC. | $77.78 | 2023-2024 | Iclusig, Ninlaro |
| Alexion Pharmaceuticals, INC. | $65.42 | 2024-2025 | Ultomiris |
| Astellas Pharma US INC | $64.21 | 2024-2025 | Vyloy, Xospata |
| Sobi, INC | $57.35 | 2024 | |
| Genzyme Corporation | $54.62 | 2025 | |
| Emd Serono, INC. | $39.79 | 2024 | |
| Merck Sharp & Dohme LLC | $38.47 | 2023-2024 | Keytruda, Prevymis, Dificid |
| Glaxosmithkline, LLC. | $32.30 | 2025 | Ojjaara |
| Genentech USA, INC. | $30.27 | 2023 | Venclexta |
| Amgen INC. | $28.00 | 2022 | |
| Pharmaessentia USA Corporation | $25.60 | 2024 | Besremi |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $25.28 | 2024 | |
| Celgene Corporation | $24.50 | 2021 | |
| Seagen INC. | $19.71 | 2022 | |
| Galderma Laboratories, L.P. | $19.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvia Yoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.